Skip to main
BCAX
BCAX logo

BCAX Stock Forecast & Price Target

BCAX Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 20%
Buy 60%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Bicara Therapeutics Inc. has demonstrated a promising therapeutic profile for its bifunctional antibody, ficerafusp alfa, particularly in its combination with Keytruda, showing a progression-free survival (mPFS) of 9.9 months and an overall survival (mOS) of 21.3 months. This performance is notably superior to the outcomes observed with Keytruda alone or in combination with chemotherapy, where lower overall response rates (ORR) of 19.1% and 38.0% respectively were reported. Given these strong clinical results, the prospect of ficerafusp alfa as a transformative treatment option points to a favorable growth trajectory for Bicara Therapeutics's stock.

Bears say

Bicara Therapeutics Inc reported a net loss of $0.50 per share for the second quarter of 2025, which aligns closely with prior estimates of $0.51 per share, indicating ongoing financial challenges. Key risks impacting the company's outlook include potential negative clinical results for the pipeline candidate ficerafusp alfa, delays in progressing it into registrational trials, and the possibility of not obtaining regulatory approvals in a timely manner. Additionally, the increasing competition in the bispecific antibody space and concerns regarding long-term dilution pose further threats to the company’s financial stability.

BCAX has been analyzed by 5 analysts, with a consensus rating of Buy. 20% of analysts recommend a Strong Buy, 60% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bicara Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bicara Therapeutics Inc (BCAX) Forecast

Analysts have given BCAX a Buy based on their latest research and market trends.

According to 5 analysts, BCAX has a Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $26.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $26.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bicara Therapeutics Inc (BCAX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.